Dorothy E Schumm

US Patent:

48716618, Oct 3, 1989

Filed:

Jun 18, 1985

Appl. No.:

6/745924

Inventors:

Thomas E. Webb - Columbus OH
Dorothy E. Schumm - Columbus OH
Zbigniew Walaszek - Columbus OH
Raymond W. Lang - Columbus OH

Assignee:

The Ohio State University Research Foundation - Columbus OH

International Classification:

C12Q 100
C12Q 102
G01N 33564
G01N 3353

US Classification:

435 7

Abstract:

Materials can be screened for carcinogenic properties by administering them to test animals and assaying biological tissue, preferably plasma, for the presence of a 60K cancer-associated phosphoprotein. The test is applicable to a wide range of chemically-diverse carcinogens and is not restricted to carcinogens having one particular mode of action.

US Patent:

47465395, May 24, 1988

Filed:

Nov 23, 1983

Appl. No.:

6/554439

Inventors:

Thomas E. Webb - Columbus OH
Dorothy E. Schumm - Columbus OH

Assignee:

The Ohio State University Research Foundation - Columbus OH

International Classification:

C12Q 100
C12P 2100
C12P 2102
A61K 3900

US Classification:

424 85

Abstract:

It has previously been shown that the serum from patients suffering from a wide range of cancers contains a cancer marker protein having the ability to release RNA from cell nuclei. This cancer marker protein is purified by taking the protein fraction precipitating between 30% and 50% saturated aqueous ammonium sulfate solution, dialyzing a solution of the protein fraction against TMK buffer, chromatographing the dialyzed protein on a molecular sieve and isolating the fraction having a molecular weight of about 60,000; and removing albumin. Injection of the purified protein into rabbits, preparation of serum from blood of the rabbits and absorption of the sera with normal plasma fraction produces at antibody specific to the cancer marker protein and therefore useful in a radioimmunoassay or ELISA test for a wide variety of cancers. Monoclonal antibody preparations to the protein may be prepared by injecting the purified protein into mice, harvesting the spleen and lymph node cells, fusing these cells with mouse myeloma cells and using the resultant hybridoma cells to produce the monoclonal antibody.

US Patent:

56564449, Aug 12, 1997

Filed:

May 26, 1995

Appl. No.:

8/451923

Inventors:

Thomas E. Webb - Columbus OH
Paul C. Stromberg - Westerville OH
Dorothy E. Schumm - Patriot OH

Assignee:

The Ohio State University - Columbus OH

International Classification:

G01N 33574
G01N 3353
C07K 1630
C07K 1618

US Classification:

435 723

Abstract:

The present invention provides a low cost, less toxic, anti-cancer immunotherapy which enhances the host's immune system ability to destroy or contain cancers, and also provides a diagnostic test for cancer. Specifically, the present invention provides monoclonal antibodies specific for, that is, specifically bind, oncofetal protein (OFP), a cancer cell product. Tumors treated with a single dose of the monoclonal antibodies against OFP are markedly reduced in size, and leukemic populations of cells treated with a single does of monoclonal antibodies against OFP are significantly decreased in number. Since the monoclonal antibodies of the present invention do not bind to tumor cells, the monoclonal antibody treatment overcomes the disadvantages associated with tumor cell targeting. Monoclonal antibodies to OFP offer a simple and inexpensive agent for use as a primary or adjuvant therapy against a wide variety of cancers and tumors in humans and other animals. The monoclonal antibodies against OFP are also employed to detect cancer in animal, including human patients.

US Patent:

56885059, Nov 18, 1997

Filed:

May 24, 1995

Appl. No.:

8/449336

Inventors:

Thomas E. Webb - Columbus OH
Paul C. Stromberg - Westerville OH
Dorothy E. Schumm - Patriot OH

Assignee:

The Ohio State University - Columbus OH

International Classification:

A61K 39395
C07K 1600
C07K 1618
C07K 1630

US Classification:

4241451

Abstract:

The present invention provides a low cost, less toxic, anti-cancer immunotherapy which enhances the host's immune system ability to destroy or contain cancers, and also provides a diagnostic test for cancer. Specifically, the present invention provides monoclonal antibodies specific for, that is, specifically bind, oncofetal protein (OFP), a cancer cell product. Tumors treated with a single dose of the monoclonal antibodies against OFP are markedly reduced in size, and leukemic populations of cells treated with a single does of monoclonal antibodies against OFP are significantly decreased in number. Since the monoclonal antibodies of the present invention do not bind to tumor cells, the monoclonal antibody treatment overcomes the disadvantages associated with tumor cell targeting. Monoclonal antibodies to OFP offer a simple and inexpensive agent for use as a primary or adjuvant therapy against a wide variety of cancers and tumors in humans and other animals. The monoclonal antibodies against OFP are also employed to detect cancer in animal, including human patients.

US Patent:

56503008, Jul 22, 1997

Filed:

May 26, 1995

Appl. No.:

8/452252

Inventors:

Thomas E. Webb - Columbus OH
Paul C. Stromberg - Westerville OH
Dorothy E. Schumm - Patriot OH

Assignee:

The Ohio State University - Columbus OH

International Classification:

C12P 2108
C12N 512
C07K 1618
C07K 1630

US Classification:

435 7021

Abstract:

The present invention provides a low cost, less toxic, anti-cancer immunotherapy which enhances the host's immune system ability to destroy or contain cancers, and also provides a diagnostic test for cancer. Specifically, the present invention provides monoclonal antibodies specific for, that is, specifically bind, oncofetal protein (OFP), a cancer cell product. Tumors treated with a single dose of the monoclonal antibodies against OFP are markedly reduced in size, and leukemic populations of cells treated with a single does of monoclonal antibodies against OFP are significantly decreased in number. Since the monoclonal antibodies of the present invention do not bind to tumor cells, the monoclonal antibody treatment overcomes the disadvantages associated with tumor cell targeting. Monoclonal antibodies to OFP offer a simple and inexpensive agent for use as a primary or adjuvant therapy against a wide variety of cancers and tumors in humans and other animals. The monoclonal antibodies against OFP are also employed to detect cancer in animal, including human patients.